Gilead Sciences Inc (GILD) FY2025Q3 Earning Prediction

10/30 04:00:00

After Hours

Gilead Sciences Inc (GILD) is set to release its FY2025Q3 earnings performance on 10/30 04:00:00 in After Hours trading. Consensus forecasts predict a revenue of 7.46B and an earnings per share (EPS) of 2.15 for the FY2025Q3. With Intellectia's exclusive AI algorithms, users can predict whether the earnings will beat or miss expectations before the report drops. Leverage this powerful tool to strategize and position your trades ahead of the earnings release!

Estimate

Actual

Surprise

RevenueBEAT

7.46B

7.77B

+4.16%

EPSBEAT

2.15

2.47

+14.88%

AI Earnings Prediction

Prediction for FY2025Q3

Earnings Date: Oct 30, 2025

The earnings prediction leans towards a Beat, driven by strong performance in the HIV franchise and upward revisions for Trodelvy, despite minor setbacks in policy and pipeline.

Beat

Last 0 quarters:

4 beats1 misses

Scenario Analysis

The AI analyzes the probability of each scenario occurring and identifies the triggering conditions.

Scenario

Prob.

Stock Reaction

Trigger Condition

Strong Beat

20%

+5-7%

Yeztugo sales materially beat + HHS mandates coverage.

Beat

45%

+2-4%

HIV growth offsets cell therapy/Veklury misses.

Neutral

20%

Flat

CVS exclusion drags Yeztugo + cell therapy underperforms.

Miss

10%

-3-5%

Policy fears (Biktarvy pricing) materialize.

Strong Miss

-7-10%

Dual shock from HIV sales miss + accelerated Veklury decline.

Unlock Free Scenario Probability

Key Indicators Forecast

The AI provides itemized forecasts for key indicators, potentially including revenue, EPS, gross margin, and free cash flow.

Revenue

EPS

Currency:

No data

Actual

Estimate

Metric

Prediction

Justification

Revenue

Beat

Yeztugo’s robust launch and Trodelvy’s upward estimate revisions offset Veklury/cell therapy declines.

EPS

Beat

Higher HIV sales and cost controls mitigate acquisition-related dilution ($0.23-$0.25 EPS impact).

Unlock Free Key Indicators Forecast

Prediction Logic & Rational

Logic & Justification
Key Fact Data Insights:

HIV Franchise Strength:

Positive Yeztugo Launch: Citi’s physician survey indicates strong initial demand for Yeztugo, prompting raised sales forecasts.
Biktarvy’s Sustained Efficacy: 5-year data from the BICSTaR study confirms durable viral suppression, supporting continued adoption.
EC Approval for Yeytuo: New twice-yearly PrEP option in Europe (approved Aug 2025) adds long-term revenue potential, though Q3 impact may be limited.

Trodelvy Momentum:

TD Cowen upgraded estimates for Trodelvy, citing improved oncology outlook.

Policy and Pipeline Risks:

CVS’s exclusion of Yeztugo from coverage is a near-term headwind, but analysts expect eventual HHS-mandated access (Leerink).
Phase 1 trial termination for ’1219 (HIV injectable) is a pipeline setback but deemed non-material to near-term performance.

Cell Therapy Weakness:

Galapagos winding down cell therapy business signals broader sector challenges. Gilead’s acquisition of Interius Bio (CAR-T) is long-term focused and dilutive to 2025 EPS.
Consensus Context:
Revenue/EPS revisions are modest (+ 0.1%/+ 0.88%), suggesting low expectations. Stock underperformance vs. S&P 500 (- 4.1% relative) implies muted positioning, lowering the bar for a Beat.

Prediction Logic & Rational

Tactical Strategy Recommendations

Trading Strategy

Stock: Accumulate ahead of earnings. Low expectations and HIV momentum suggest asymmetric upside.
Options:
- Bull Call Spread: Buy Nov $125 calls / Sell Nov $130 calls to capitalize on a Beat while limiting premium outlay.
- Hedge: Long puts at $115 as protection against policy risks.
Caution: Monitor HHS commentary on Yeztugo coverage and Trump administration drug pricing rhetoric.
Rationale: The setup favors a Beat driven by HIV franchise resilience, but policy and pipeline risks warrant defined-risk strategies.

Tactical Strategy Recommendations

Earnings Surprise Analysis

The chart displays the extent of earnings surprises and corresponding stock price movements for each earnings event.

Revenue

EPS

GILD Transcript

Gilead Sciences, Inc. (GILD) Presents at Evercore 8th Annual Healthcare Conference Transcript

Neutral12-3

Gilead Sciences, Inc. (GILD) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Neutral12-3

Gilead Sciences, Inc. (GILD) Presents at Jefferies London Healthcare Conference 2025 Transcript

Neutral11-19

Gilead Sciences, Inc. (GILD) Presents at UBS Global Healthcare Conference 2025 Transcript

Neutral11-10

GILD Slides

Gilead Q225 slides: HIV strength drives guidance raise, oncology pipeline advances

2025-08-07

Gilead Q3 2025 slides: HIV strength drives guidance raise, new products gain traction

2025-10-30

GILD Report

GILEAD SCIENCES, INC. 10-Q

10-Q

2024-11-12

GILEAD SCIENCES, INC. 10-Q

10-Q

2024-05-08

GILEAD SCIENCES, INC. 10-K

10-K

2024-02-23

GILEAD SCIENCES, INC. 10-Q

10-Q

2023-11-07

Frequently Asked Questions

What is the Gilead Sciences Inc FY2025Q3 Earnings Release Date and Time?

Gilead Sciences Inc (GILD) is scheduled to release its FY2025Q3 earnings report onOct 30, 2025, After Hours(approximately 4:00 PM ET). This timing allows investors to react during after-hours trading, with a conference call typically following shortly after.

What Are the Consensus Forecasts for Gilead Sciences Inc FY2025Q3 Revenue and EPS?

Analysts' consensus predicts 7.46B in revenue and an EPS of 2.15 for Gilead Sciences Inc's FY2025Q3.

What Does Intellectia's AI Predict for Gilead Sciences Inc FY2025Q3 Earnings?

Intellectia's exclusive AI algorithms forecast a Beat forGilead Sciences Inc's FY2025Q3 earnings, with a prediction date of Oct 30, 2025. Gilead Sciences Inc The earnings prediction leans towards a Beat, driven by strong performance in the HIV franchise and upward revisions for Trodelvy, despite minor setbacks in policy and pipeline.

How Can I Use This Earnings Prediction to Trade GILD Stock?

Leverage Intellectia's AI forecast to position trades ahead of theOct 30, 2025 release—consider calls for a beat scenario or protective puts for misses. Focus on pre-market volatility, and use the scenario probabilities to build strategies around revenue and guidance updates.

How Accurate Is Intellectia's AI for Earnings Predictions Like Gilead Sciences Inc FY2025Q3?

Intellectia's predictions are backed by rigorous backtesting, showing a high hit rate for Beat and Miss calls compared to traditional analysis. While no forecast is 100% certain, we provide probability-based scenarios (e.g., 50% chance of a *Beat*) and detailed rationales to help you make informed decisions. Combine our insights with your strategy for the best results—it's like having a co-pilot for earnings season! Empowering users to strategize trades before reports drop.

How does AI Earnings Prediction generate its forecasts?

AI Earnings Prediction uses advanced Large Language Models (LLMs) to analyze a wealth of data, including past earnings transcripts, real-time market sentiment, analyst insights, and company news from the last three months. It focuses on key indicators like revenue, EPS, and margins to predict whether a company will *Beat*, *Miss*, or remain Neutral relative to market expectations. Think of it as a super-smart analyst crunching numbers and news 24/7 to give you a trading edge!

When are the predictions available, and how often are they updated?

Predictions are generated two days before a company’s earnings release (e.g., 5:00 PM ET on Feb 13 for a Feb 15 report) to capture the latest market and company data. They’re updated in real-time if significant news breaks, ensuring you get fresh insights.

Can I use AI Earnings Prediction for all types of stocks?

Currently, AI Earnings Prediction focuses on companies with market caps above $40 billion, covering major players like SPG, AAPL, MSFT, and NVDA for the 2024-2025 earnings seasons. We prioritize high-impact stocks with robust data to ensure reliable forecasts. Stay tuned as we expand coverage to more companies based on user demand!